EFFICACY AND SAFETY OF FLUOXETINE IN PATIENTS WITH UROLOGIC DISEASE: A COMPARATIVE TREATMENT ANALYSI

Abstract

Resume. Relevance: Premature ejaculation (PE) remains a complex polyetiological disease destabilizing the sexual function of men. Its prevalence is estimated at 20-40%. The diagnosis of PE is difficult because its symptoms are largely subjective and poorly defined in the clinical context. Pharmacotherapy is used as the main method of therapy. Objective: Comparative evaluation of the efficacy and safety of Clomipramine hydrochloride (2.5 mg nasal spray) and Fluoxetine (20 mg capsules) in the treatment of patients with premature ejaculation. Methods: The study involved 672 men aged 18 to 60 years (average age 36.4±3.7 years) with complaints of PE. The respondents were surveyed using the ques tionnaire “Uzbek PE Index" (UIPE). 101 patients were selected by random sampling to evaluate the effective ness and safety of a nasal spray containing Clomipramine hydrochloride. 103 patients were examined and treated with fluoxetine. 99 patients were in the placebo group. Results: in patients with premature ejaculation treated with clomipramine, LIVIA increases compared to patients treated with fluoxetine.